. Author manuscript; available in PMC: 2020 Aug 1.

Published in final edited form as: Endocr Relat Cancer. 2019 Aug;26(8):699–712. doi: 10.1530/ERC-19-0188

Table 1. Estimated IC₅₀ concentrations (μM) for G-5555 and FRAX1036.

The IC₅₀ for each cell line and each drug were estimated using the viability data represented in Fig. 1. Significant differences between G-5555 and FRAX1036 were calculated by inverse variance weighted t-tests when the IC₅₀ was calculable and by linear mixed models of dose-response slopes if the IC₅₀ was >10 μM.

Estimated IC₅₀ concentrations (μM) for G-5555 and FRAX1036 in human thyroid cancer cell lines
Cell Line	G-5555 (μM)	Std Err	95% CI	FRAX1036 (μM)	Std Err	95% CI
TPC1	0.50^***	0.04	(0.41, 0.59)	3.94	0.36	(3.08, 4.80)
BCPAP	2.46^***	0.49	(1.31, 3.60)	7.73	0.31	(6.96, 8.49)
HTh74	3.36^***	0.25	(2.72, 4.01)	6.14	0.35	(5.17, 7.10)
SW1736	1.37^***	0.10	(1.12, 1.62)	>10
8505C	6.64^***	0.54	(5.40, 7.88)	>10
K1	6.98^***	0.65	(5.32, 8.65)	>10
FTC133	>10^**			>10
THJ-16T	2.60^***	0.40	(1.83, 3.38)	>10

^***

P ≤ 0.001

^**

P ≤ 0.01.

Table 1. Estimated IC50 concentrations (μM) for G-5555 and FRAX1036.

Table 1. Estimated IC₅₀ concentrations (μM) for G-5555 and FRAX1036.